A consensus introduction to serum replacements and serum-free media for cellular therapies

Ohad Karnieli, Oryan Makler Friedner, Julie G. Allickson, Nan Zhang, Sunghoon Jung, David Fiorentini, Eytan Abraham, Shannon S. Eaker, Tan Kah Yong, Allan Chan, Sarah Griffiths, Amy k. When, Steve Oh, Ohad Karnieli

Research output: Contribution to journalReview articlepeer-review

Abstract

The cell therapy industry is a fast-growing industry targeted toward a myriad of clinical indications. As the cell therapy industry matures and clinical trials hit their pivotal Phase 3 studies, there will be a significant need for scale-up, process validation, and critical raw material quality assurance. Part of the well discussed challenges of upscaling manufacturing processes there is a less discussed issue relating to the availability of raw materials in the needed quality and quantities. The FDA recently noted that over 80% of the 66 investigational new drug (IND) applications for mesenchymal stem cell (MSC) products analyzed described the use of FBS during manufacturing. Accumulated data from the past years show an acceleration in serum consumption by at least 10%-15% annually, which suggests that the global demand for serum may soon exceed the supply. Ongoing concerns of safety issues due to risks of various pathogen contaminations, as well as issues related to the aforementioned serum variability that can affect final product reproducibility, are strong motivators to search for serum substitutes or serum-free media. it is important to note that there are no accepted definitions for most of these terms which leads to misleading's and misunderstandings, where the same term might be defined differently by different vendors, manufacturer, and users. It is the drug developer's responsibility to clarify what the supplied labels mean and to identify the correct questions and audits to ensure quality. The paper reviews the available serum replacements, main components, basic strategies for replacement of serum and suggests definitions.

Original languageEnglish (US)
Pages (from-to)155-169
Number of pages15
JournalCytotherapy
Volume19
Issue number2
DOIs
StatePublished - Feb 1 2017

Keywords

  • animal component free
  • cell therapy
  • cGMP media
  • defined media
  • fetal bovine serum
  • human serum
  • platelet lysate
  • serum free
  • serum replacement
  • xeno free

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Genetics(clinical)
  • Cell Biology
  • Cancer Research
  • Transplantation

Fingerprint

Dive into the research topics of 'A consensus introduction to serum replacements and serum-free media for cellular therapies'. Together they form a unique fingerprint.

Cite this